Skip to main content

Table 2 89 Zr-bevacizumab uptake parameters

From: Pilot study of 89Zr-bevacizumab positron emission tomography in patients with advanced non-small cell lung cancer

 

Tumorous tissue

Blood (AD)

Non-tumorous tissue

PT

LNM

NLNM

Muscle

Fat

Lung

Day 4

       

 SUVpeak

4.3

4.0

5.0

3.9

1.0

0.6

0.8

(2.1 to 6.9)

(2.1 to 12.1)

(2.9 to 14.5)

(1.7 to 4.9)

(0.4 to 1.1)

(0.3 to 0.7)

(0.5 to 1.4)

 TBR

1.2

1.1

1.2

 

0.3

0.2

0.3

(0.7 to 1.8)

(0.8 to 7.2)

(0.7 to 8.6)

 

(0.1 to 0.3)

(0.1 to 0.2)

(0.2 to 0.3)

Day 7

       

 SUVpeak

3.3

2.7

3.9

1.4

0.5

0.4

0.4

(0.7 to 4.9)

(1.0 to 9.0)

(1.1 to 9.7)

(0.9 to 3.5)

(0.2 to 1.3)

(0.1 to 0.6)

(0.2 to 1.1)

 TBR

0.8

1.6

1.9

 

0.5

0.3

0.4

(1.0 to 4.0)

(1.1 to 15.3)

(0.9 to 16.5)

 

(0.3 to 0.6)

(0.1 to 0.4)

(0.2 to 0.6)

  1. AD, aorta descendens; LNM, lymph node metastases; NLNM, non-lymph node metastases; PT, primary tumor; TBR, tumor-to-blood ratio. Median (range) is shown.